Immunocore (NASDAQ:IMCR) Shares Down 8.6%

Shares of Immunocore Holdings plc (NASDAQ:IMCR) fell 8.6% during trading on Friday . The company traded as low as $22.01 and last traded at $22.01. 3,588 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 78,343 shares. The stock had previously closed at $24.09.

Several research firms recently issued reports on IMCR. Oppenheimer began coverage on shares of Immunocore in a research note on Tuesday, October 19th. They set an “outperform” rating and a $56.00 price target on the stock. Zacks Investment Research raised shares of Immunocore from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a research note on Wednesday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $50.20.

The business’s 50 day moving average price is $33.93 and its two-hundred day moving average price is $34.72. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.31.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, November 10th. The company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.15. The company had revenue of $8.17 million during the quarter, compared to analyst estimates of $6.92 million. Research analysts anticipate that Immunocore Holdings plc will post -3.95 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP raised its holdings in shares of Immunocore by 2.1% during the third quarter. Rock Springs Capital Management LP now owns 2,445,155 shares of the company’s stock valued at $90,642,000 after acquiring an additional 50,370 shares during the period. Wellington Management Group LLP grew its position in Immunocore by 260.9% during the third quarter. Wellington Management Group LLP now owns 1,052,075 shares of the company’s stock valued at $39,000,000 after purchasing an additional 760,563 shares in the last quarter. Bain Capital Public Equity Management II LLC grew its position in Immunocore by 34.5% during the third quarter. Bain Capital Public Equity Management II LLC now owns 638,205 shares of the company’s stock valued at $23,658,000 after purchasing an additional 163,651 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Immunocore by 0.4% during the third quarter. Thrivent Financial for Lutherans now owns 350,214 shares of the company’s stock valued at $12,983,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Immunocore by 245.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 335,512 shares of the company’s stock valued at $12,437,000 after purchasing an additional 238,286 shares in the last quarter. Institutional investors and hedge funds own 44.09% of the company’s stock.

Immunocore Company Profile (NASDAQ:IMCR)

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

See Also: Hedge Funds – How They Work For Investors

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.